People in the News

Nov 30, 2018

Joan Martin

Joan Martin has joined Ortho Clinical Diagnostics as vice president of Europe, the Middle East, and Africa. He will be in charge of the company's commercial operations in the region. Martin was previously executive vice president and head of Europe, the Middle East, and Africa at Accelerate Diagnostics. 

Nov 26, 2018

Reginald Seeto

CareDx has appointed Reginald Seeto to the newly created role of president and chief business officer. Seeto has 20 years of experience in commercial operations, corporate development, and strategy, most recently serving as chief operating officer at Ardelyx. He has also worked at AstraZeneca/Medimmune and was a member of the MedImmune executive team. His responsibilities there included leading corporate development and strategy, global strategic marketing, and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. Before AstraZeneca, Seeto held positions at Organon Biosciences and at McKinsey.

Nov 19, 2018

Jason Ryan

Jason Ryan will leave his post as CFO of Foundation Medicine to become chief operating and financial officer at Magenta Therapeutics, effective January 1 of 2019. Prior to joining Foundation Medicine, he held management positions for Taligen Therapeutics, Codon Devices, and Genomics Collaborative. Ryan holds a BS in economics from Bates College and an MBA from Babson College. Foundation Medicine has not announced a successor for Ryan yet.

Nov 13, 2018

Steve Ziganti, Patrik Jeanmonod, Jack Ball, Allen Poirson

Cytek Biosciences announced Steve Ziganti has joined the firm as vice president of worlwide sales and Patrik Jeanmonod has been hired as the company's chief financial officer. 

Additionally, Jack Ball and Allen Poirson have joined Cytek's board of directors. 

Ziganti was previously VP of sales and service at BD Biosciences before retiring from that firm. Jeanmonod has previously held executive positions in finance at Covance, Bridge Pharmaceuticals, and Synteract. He is currently a board member at Seal Biosciences. 

Ball formerly was the CEO of Amnis and CCO of Accuri Cytomers and Molecular Probes. Poirson is a partner at Mighty Capital and previously was CEO of Sony Biotechnology.

Nov 08, 2018

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

Nov 07, 2018

Scott Nicholson, Cory Dunn

Biocept has appointed Scott Nicholson as its Vice President of Sales in the US and Cory Dunn as its Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets. He has served as a sales manager, executive, district manager, and regional manager in prior positions. Most recently, Nicholson was vice president of sales at GenomeDx, where he led the commercialization effort for the firm's Decipher tests.

Dunn has over 15 years of commercial marketing experience, specializing in diagnostic testing services for oncology. She most recently served as VP of commercial marketing at GenomeDx, where she led the launch, commercial marketing, and product life cycle management of the Decipher suit of tests. Prior to GenomeDx, Dunn oversaw the marketing efforts for Plus Diagnostics' Gastroenterology, Dermatology and Hematology-Oncology product lines. She holds post graduate science and education degrees from the University of California, San Diego and Stanford University, respectively.

In connection with the hirings, Biocept said it granted each individual an inducement stock option award to purchase 24,200 shares of Biocept common stock, with an exercise price per share equal to the closing price of Biocept's common stock on October 31, 2018.

Nov 05, 2018

Hillel Kahane

Acupath Laboratories has announced the appointment of Hillel Kahane as the company's chief medical officer and director of uropathology. Previously, Kahane served as medical director of Bostwick Labs from 2007 to 2018 and as executive medical director of Dianon Pathology, a Laboratory Corporation of America subsidiary, from 2000 to 2007. Kahane will join Acupath Chief Sales Officer John Cucci, Chief Financial Officer Zaleena Neice, and Chief Operating Officer Steve Kamalic on the Accupath Labs Executive Committee to help guide the company's overall strategy and vision.

Nov 05, 2018

Oved Amitay

Centogene has appointed Oved Amitay its chief business officer. He has almost 30 years of commercial and development experience with a focus on orphan drugs for patients with rare genetic diseases. Amitay joins Centogene from Arrett Neuroscience where he was president and COO. Prior to that he was VP, head of commercial at Alnylam Pharmaceuticals. 

Nov 02, 2018

Peter Collins

Peter Collins has stepped down as chief business officer and director of Premaitha Health, effective November 1. Previously, he was vice president and head of diagnostics at GlaxoSmithKline.

Nov 01, 2018

Susan Rolih

Meridian Bioscience said this week that Susan Rolih, executive VP of global regulatory and quality systems, will retire on Nov. 30, 2018. She worked for the firm for 18 years and is expected to serve as a consultant on an as-requested basis with matters related to FDA remediation efforts at the firm's Magellan Diagnostics business, among other matters.

Nov 01, 2018

Jan Groen

Liquid biopsy firm Angle has appointed Jan Groen as a non-executive director, effective Nov. 1. He is currently president and CEO of MDxHealth. Prior to joining that firm, he was president of US operations and global chief operating officer at Agendia. Groen is also a non-executive board member of SPL Medical. 

Oct 31, 2018

Maureen Cronin

HTG Molecular Diagnostics has appointed Maureen Cronin as its CSO and senior vice president, effective Nov. 16. Cronin served as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior vice president of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.

Oct 26, 2018

Betsy Hanna

Clinical Genomics has appointed Betsy Hanna as its chief commercial officer. Hanna previous served as president and chief operating officer at Origin. Prior to Origin, she held multiple positions over an eight-year period at J&J, with her most recent position as VP of global strategic marketing for Vision Care.

Oct 18, 2018

Mary Padbury, Katherine Bach Kalin

Clinical Genomics announced the appointments of Mary Padbury and Katherine Bach Kalin to its board. Padbury who will be the chairman of the board, has done intellectual property work for Australian and multinational companies. She was most recently a partner and vice chairman of law firm Ashurst. She currently is chairman of the board for Trans-Tasman IP Attorneys.

Kalin has more than 25 years of experience as a senior executive in the healthcare and professional services industries. Most recently, she led corporate strategy at Celgene. Prior to that, she held leadership roles in marketing, sales, strategy, and new bbusiness development at Johnson & Johnson.

Oct 17, 2018

Daniel Kolk

Daniel Kolk has joined XCR Diagnostics as vice president of clinical development. He previously served as senior director of product development for Hologic, where he led development and US Food and Drug Administration clearance of respiratory assays on Hologic's Panther Fusion system. Prior to this he helped develop human papillomavirus and blood screening products at Gen-Probe, which was acquired by Hologic.

Oct 16, 2018

Tom Copa

Asuragen has hired Tom Copa as its SVP, commercial operations. Copa will lead the global sales, marketing, and customer solutions teams for the firm's diagnostics products business. Prior to Asuragen, Copa served as VP of licensed technologies at Luminex, as well as spending over 16 years as a senior executive in several roles at the firm. 

Oct 15, 2018

Robert Ford

Abbott announced that Robert Ford has been named president and chief operating officer. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott's largest business.

In addition to his current responsibilities for Medical Devices, Ford will assume responsibility for all of Abbott's operating businesses. He will continue to report to the firm's Chairman and CEO Miles White.

Ford has held various management positions across several of Abbott's businesses, including Diagnostics, Nutrition, and Medical Devices. As head of the firm's Medical Devices business for the past three years, he oversaw the integration of the St. Jude Medical acquisition. He previously led Abbott's Diabetes Care business and the launch of its glucose monitoring system, FreeStyle Libre. 

Oct 12, 2018

David Stark

Parallax Diagnostics has appointed David Stark its president, the company's parent firm Parallax Health Sciences, said. Stark has more than 20 years of experience in healthcare R&D, clinical research, regulatory affairs, and marketing. He was director of development for clinical research organization Spaulding Clinical Research and director of business development, West Coast for MedSource. Before that, he was development director, West Coast for Veristat. 

Oct 12, 2018

Jane Schwebke

Talis Biomedical has appointed Jane Schwebke to its scientific advisory board. Both a professor of medicine in the infectious disease division at the University of Alabama at Birmingham and a consultant to the Jefferson County Department of Health STD clinic, Schwebke previously served as medical director of the Harborview STD Clinic in Seattle and as director for Chicago's STD/HIV Program.

Oct 11, 2018

Jörg Debatin

Jörg Debatin has been appointed chairman of the supervisory board of Hummingbird Diagnostics. Debatin previously served as VP and chief technology officer of GE Healthcare and CEO of Amedes. In addition, he has also served as the medical director and CEO of the University Hospital Hamburg-Eppendorf.

Oct 11, 2018

John Glasspool

VisionGate has appointed John Glasspool as Chief Operating and Strategy Officer and to the firm's board of directors. Glasspool is currently a member of the board of directors of Dalcor. In addition, he is an advisor to MIT Newdigs and leads the FoCUS project, looking at pricing and policy for durable oncology therapies. Glasspool's career includes executive and management responsibilities at pharmaceutical companies, including Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. Glasspool has also served on the board of directors and as president of Vaccines Europe at the Biotechnology Industry Organization.

Oct 10, 2018

Richard Yost

Owlstone Medical appointed Richard Yost to its scientific advisory board. He is a professor and head of analytical chemistry at the University of Florida and has particular expertise in tandem mass spectrometry. Yost is the co-inventor of the triple quadrupole mass spectrometer, Owlstone added. 

Oct 09, 2018

Michel Finance

Michel Finance is leaving his post as CEO of Theradiag, the company announced. No reason was given for his departure. Finance will stay on at Theradiag until Dec. 31. A search for his successor has begun. 

Oct 09, 2018

Susan Evans, Donna Edmonds

ImmunArray announced Susan Evans will become its new CEO, replacing Donna Edmonds, who will become the chair and CEO of ImmunArray's new spinoff called BrainBox Solutions based in Richmond, Virginia.

Evans began her career at Baxter Diagnostics and Dade Behring, where held various positions in R&D including senior vice president. She also held senior R&D postions in Caliper Life Sciences and Life Scan, and was vice president scientific affairs, and vice president/general manager of Beckman Coulter Genomics. 

Edmonds, meanwhile, will remain executive chair of ImmunArray. 

Oct 08, 2018

Stan Lapidus, Howard Heller, Margaret Higham

Atlas Genetics has changed its name to Binx Health and announced several additions to the company, including the appointment of Stan Lapidus as chairman of the board. Lapidus is the founder of Exact Sciences and Helicos BioSciences.

Also, Howard Heller was appointed Binx's chief medical officer while Margaret Higham was named its director of medical affairs. Heller directs infection control and prevention at the Massachusetts Institute of Technology and provides clinical care at Massachusetts General Hospital. Higham is an infectious disease expert and medical director of the Student Health Service at Tufts University.

Pages